Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases

Prostate

Volumn 68, Issue 16, 2008, Pages 1790-1797

  Robbins, Christiane M ^a   Hernandez, Wenndy ^b   Ahaghotu, Chiledum ^c   Bennett, James ^d   Hoke, Gerald ^e   Mason, Terry ^f   Pettaway, Curtis A ^g   Vijayakumar, Srinivasan ^h   Weinrich, Sally ⁱ   Furbert Harris, Paulette ^j   Dunston, Georgia ^j   Powell, Isaac J ^k   Carpten, John D ^a   Kittles, Rick A ^b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HOWARD UNIVERSITY   (United States)

^d Midtown Urology   (United States)

^e Department of Orthopaedic Surgery   (United States)

^f MICHAEL REESE HOSPITAL   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

African American; Genetic susceptibility; HPC2 ELAC2; Prostate cancer; RNASEL

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; ELAC2 GENE; GENE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HPC2 GENE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RNASEL GNE; CASE CONTROL STUDY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ELAC2 PROTEIN, HUMAN; PPPA(2'P5'A)N DEPENDENT RIBONUCLEASE; PPPA(2'P5'A)N-DEPENDENT RIBONUCLEASE; RIBONUCLEASE; TUMOR PROTEIN;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENDORIBONUCLEASES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 56049121918     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20841     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
2. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17(4):337-347.
3. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome17p. Nat Genet 2001;27(2):172-180.
4. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30(2):181-184.
5. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32(2):321-325.
6. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10(9):943-947.
7. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004;25(6):961-966.
8. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol 2000; S68-S77.
9. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F. African-American heredity prostate cancer study: A model for genetic research. J Natl Med Assoc 2001;93(4):120-123.
10. Shriver MD, Parra EJ, Dios S, Bonilla C, Norton H, Jovel C, Pfaff C, Jones C, Massac A, Cameron N, Baron A, Jackson T, Argyropoulos G, Jin L, Hoggart CJ, McKeigue PM, Kittles RA. Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet 2003;112(4):387-399.
11. Bonilla C, Parra EJ, Pfaff CL, Dios S, Marshall JA, Hamman RF, Ferrell RE, Hoggart CL, McKeigue PM, Shriver MD. Admixture in the Hispanics of the San Luis Valley, Colorado, and its implications for complex trait gene mapping. Ann Hum Genet 2004;68: (Pt 2):139-153.
12. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 2006;43(6):507-511.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81(3):559-575.
14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21(2):263-265.
15. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. Genetics 2003;164(4):1567-1587.
16. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67(4):1014-1019.
17. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70(5):1299-1304.
18. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001;68(4):912-917.
19. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68(4):901-911.
20. Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y, Ichikawa T, Takahashi S, Shuin T, Habuchi T, Ogawa O, Inoue K, Skolnick MH, Swensen J, Camp NJ, Tavtigian SV. Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese case-control series. J Hum Genet 2002;47(12):641-648.
21. Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS, Eeles RA. HPC2/ELAC2 polymorphisms and prostate cancer risk: Analysis by age of onset of disease. Br J Cancer 2002;87(8):905-908.
22. Shea PR, Ferrell RE, Patrick AL, Kuller LH, Bunker CH. ELAC2 and,prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet 2002;111(4-5):398-400.
23. Suzuki K, Ohtake N, Nakata S, Takei T, Matsui H, Ono Y, Nakazato H, Hasumi M, Koike H, Ito K, Fukabori Y, Kurokawa K, Yamanaka H. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Anticancer Res 2002;22(6B):3507-3511.
24. Adler D, Kanji N, Trpkov K, Fick G, Hughes RM. HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet 2003;48(12):634-638.
25. Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, Hopper JL. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003;95(11):818-824.
26. Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev 2003;12(9):876-881.
27. Takahashi H, Lu W, Watanabe M, Katoh T, Furusato M, Tsukino H, Nakao H, Sudo A, Suzuki H, Akakura K, Ikemoto I, Asano K, Ito T, Wakui S, Muto T, Hano H. Ser217Leu polymorphismof the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Int J Cancer 2003;107(2):224-228.
28. Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H, Mori M, Naito S. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate 2004;61(3):248-252.
29. Chen YC, Giovannucci E, Kraft P, Hunter DJ. Sequence variants of elaC homolog 2 (E. coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study. Carcinogenesis 2008;29(5):999-1004.
30. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61(16):6038-6041.
31. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001;61(13):4982-4984.
32. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61(17):6494-6499.
33. Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer. Genet Epidemiol 2005;28(3):232-243.
34. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002;71(1):116-123.
35. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr-Urtreger A. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002;71(4):981-984.
36. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 2003;89(4):691-696.
37. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, Vogel W, Paiss T. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 2005;92(6):1159-1164.
38. Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15(3):474-479.
39. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 2007;67(8):849-854.
40. Larson BT, Magi-Galluzzi C, Casey G, Plummer SJ, Silverman R, Klein EA. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 2008;179(4):1344-1348.
41. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: A meta-analysis. Clin Cancer Res 2006;12(19):5713-5719.
42. Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, Adami HO, Augustsson-Balter K, Gronberg H. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004;10(21):7150-7156.
43. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007;13(19):5959-5964.
44. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32(4):581-583.
45. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2(3):e25.